Connection
Adam Gilden to Anti-Obesity Agents
This is a "connection" page, showing publications Adam Gilden has written about Anti-Obesity Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.228 |
|
|
|
-
Gilden AH, Catenacci VA, Taormina JM. Obesity. Ann Intern Med. 2024 05; 177(5):ITC65-ITC80.
Score: 0.806
-
Chao AM, Gilden A, Wadden TA. Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. PLoS Med. 2026 Jan; 23(1):e1004871.
Score: 0.226
-
Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, Leonard S, Jakicic JM. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023 Dec; 12(4):453-473.
Score: 0.195